{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T09:11:45Z","timestamp":1789031505267,"version":"build-2803163510"},"reference-count":110,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015326","name":"National Institutes of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["DK123078-01A1"],"award-info":[{"award-number":["DK123078-01A1"]}],"id":[{"id":"10.13039\/100015326","id-type":"DOI","asserted-by":"publisher"}]},{"award":["DK123078-01A1"],"award-info":[{"award-number":["DK123078-01A1"]}],"id":[{"id":"https:\/\/ror.org\/00adh9b73","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathophysiology"],"abstract":"<jats:p>Sodium glucose cotransporter-2 inhibitors (SGLT2is) have rapidly evolved from glucose-lowering agents to multifaceted therapies with significant renoprotective and cardioprotective potential. Although originally developed to inhibit glucose reabsorption within the renal proximal tubule for the treatment of Type 2 diabetes mellitus (T2DM), growing evidence indicates that SGLT2is exert broad systemic actions extending beyond glycemic control. Among this drug class, dapagliflozin has emerged as a clinically important agent with pleiotropic effects involving renal hemodynamics, inflammatory signaling, mitochondrial function, fibrosis regulation, and cellular stress adaptation. This review outlines the historical progression from the discovery of phlorizin to the development of highly selective modern SGLT2 inhibitors while emphasizing mechanistic insights gained from experimental and clinical studies of dapagliflozin. In addition to the established effects on sodium\u2013glucose transport, dapagliflozin modulates multiple epithelial transport proteins including NHE3, NaPi-2a, NCC, and NCX1, highlighting complex regulatory effects on sodium handling and tubular electrolyte transport. Emerging evidence further demonstrates that dapagliflozin suppresses inflammatory and profibrotic pathways involving YAP\/TAZ, STAT1, TGF-\u03b2, NLRP3, and NF-KB signaling. Restoration of tubuloglomerular feedback, attenuation of oxidative stress, and preservation of mitochondrial function also appear to contribute substantially to the renoprotective actions of SGLT2 inhibition. Beyond the kidney, dapagliflozin and related SGLT2is exert cardioprotective effects through coordinated improvements in cardiac energetics, inflammatory regulation, and hemodynamic function. Emerging studies additionally suggest potential pulmonary benefits, including reductions in inflammatory signaling, pulmonary edema, and respiratory complications. Collectively, these findings support a shift in understanding SGLT2is from targeted metabolic therapies to broader regulators of cellular and organ function. Continued investigation into the glucose-independent mechanisms of dapagliflozin may reveal additional therapeutic applications across chronic metabolic, cardiovascular, and inflammatory diseases.<\/jats:p>","DOI":"10.3390\/pathophysiology33030068","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T08:07:41Z","timestamp":1789027661000},"page":"68","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dapagliflozin Beyond Glucose Lowering: Mechanisms of Renal and Systemic Protection"],"prefix":"10.3390","volume":"33","author":[{"given":"Madison L.","family":"Wise","sequence":"first","affiliation":[{"name":"Division of Nephrology, Hypertension, and Renal Transplantation, Department of Medicine, University of Florida College of Medicine, Gainesville, FL 32610, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4381-1172","authenticated-orcid":false,"given":"Abdel A.","family":"Alli","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Hypertension, and Renal Transplantation, Department of Medicine, University of Florida College of Medicine, Gainesville, FL 32610, USA"},{"name":"Department of Physiology and Aging, University of Florida College of Medicine, Gainesville, FL 32610, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"American Diabetes Association (2014). Diagnosis and classification of diabetes mellitus. Diabetes Care, 37, S81\u2013S90.","DOI":"10.2337\/dc14-S081"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"107843","DOI":"10.1016\/j.diabres.2019.107843","article-title":"Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition","volume":"157","author":"Saeedi","year":"2019","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_3","first-page":"127","article-title":"The Treatment of Diabetes with Insulin","volume":"30","author":"Meakins","year":"1923","journal-title":"Edinb. Med. J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e001115","DOI":"10.1136\/bmjdrc-2019-001115","article-title":"Flash glucose monitoring helps achieve better glycemic control than conventional self-monitoring of blood glucose in non-insulin-treated type 2 diabetes: A randomized controlled trial","volume":"8","author":"Wada","year":"2020","journal-title":"BMJ Open Diabetes Res. Care"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/clpt.2008.250","article-title":"Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus","volume":"85","author":"Komoroski","year":"2009","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Maisto, M., Piccolo, V., Novellino, E., Schiano, E., Iannuzzo, F., Ciampaglia, R., Summa, V., and Tenore, G.C. (2022). Optimization of Phlorizin Extraction from Annurca Apple Tree Leaves Using Response Surface Methodology. Antioxidants, 11.","DOI":"10.3390\/antiox11101933"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1172\/JCI100559","article-title":"The Action of Phlorizin on the Excretion of Glucose, Xylose, Sucrose, Creatinine and Urea by Man","volume":"12","author":"Chasis","year":"1933","journal-title":"J. Clin. Investig."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1113\/jphysiol.1923.sp002085","article-title":"On the action of phlorhizin on the kidney","volume":"57","author":"Mayrs","year":"1923","journal-title":"J. Physiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1172\/JCI100618","article-title":"The Effects on Renal Activity of the Oral Administration of Phlorizin in Man","volume":"13","author":"Goldring","year":"1934","journal-title":"J. Clin. Investig."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/0006-3002(62)90543-7","article-title":"Phlorizin as a competitive inhibitor of the active transport of sugars by hamster small intestine, in vitro","volume":"56","author":"Alvarado","year":"1962","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/0005-2736(75)90028-0","article-title":"Inhibition of glucose transport into brain by phlorizin, phloretin and glucose analogues","volume":"406","author":"Betz","year":"1975","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/330379a0","article-title":"Expression cloning and cDNA sequencing of the Na+\/glucose co-transporter","volume":"330","author":"Hediger","year":"1987","journal-title":"Nature"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1172\/JCI116972","article-title":"The human kidney low affinity Na+\/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose","volume":"93","author":"Kanai","year":"1994","journal-title":"J. Clin. Investig."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/350354a0","article-title":"Glucose\/galactose malabsorption caused by a defect in the Na+\/glucose cotransporter","volume":"350","author":"Turk","year":"1991","journal-title":"Nature"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s002329900121","article-title":"Sugar transport heterogeneity in the kidney: Two independent transporters or different transport modes through an oligomeric Protein? 1. Glucose transport studies","volume":"153","author":"Oulianova","year":"1996","journal-title":"J. Membr. Biol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"27099","DOI":"10.1074\/jbc.270.45.27099","article-title":"Kinetics of steady-state currents and charge movements associated with the rat Na+\/glucose cotransporter","volume":"270","author":"Loo","year":"1995","journal-title":"J. Biol. Chem."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"29365","DOI":"10.1074\/jbc.270.49.29365","article-title":"Molecular characteristics of Na+-coupled glucose transporters in adult and embryonic rat kidney","volume":"270","author":"You","year":"1995","journal-title":"J. Biol. Chem."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.2337\/diabetes.48.9.1794","article-title":"T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes","volume":"48","author":"Oku","year":"1999","journal-title":"Diabetes"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12933-018-0741-9","article-title":"Dual inhibition of sodium-glucose linked cotransporters 1 and 2 exacerbates cardiac dysfunction following experimental myocardial infarction","volume":"17","author":"Connelly","year":"2018","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1097\/01.ASN.0000092790.89332.D2","article-title":"Molecular analysis of the SGLT2 gene in patients with renal glucosuria","volume":"14","author":"Santer","year":"2003","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1463-1326.2011.01517.x","article-title":"Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: Characterisation and comparison with other SGLT-2 inhibitors","volume":"14","author":"Grempler","year":"2012","journal-title":"Diabetes Obes. Metab."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1021\/jm701272q","article-title":"Discovery of dapagliflozin: A potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes","volume":"51","author":"Meng","year":"2008","journal-title":"J. Med. Chem."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"6355","DOI":"10.1021\/jm100332n","article-title":"Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus","volume":"53","author":"Nomura","year":"2010","journal-title":"J. Med. Chem."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/dom.12460","article-title":"Dose-ranging efficacy and safety study of ertugliflozin, a sodium-glucose co-transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin","volume":"17","author":"Amin","year":"2015","journal-title":"Diabetes Obes. Metab."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in Patients with Chronic Kidney Disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"C1174","DOI":"10.1152\/ajpcell.00450.2011","article-title":"Expression of Na+-D-glucose cotransporter SGLT2 in rodents is kidney-specific and exhibits sex and species differences","volume":"302","author":"Sabolic","year":"2012","journal-title":"Am. J. Physiol.-Cell Physiol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"F188","DOI":"10.1152\/ajprenal.00518.2013","article-title":"Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia","volume":"306","author":"Rieg","year":"2014","journal-title":"Am. J. Physiol.-Ren. Physiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"C14","DOI":"10.1152\/ajpcell.00388.2010","article-title":"Glucose transport by human renal Na+\/D-glucose cotransporters SGLT1 and SGLT2","volume":"300","author":"Hummel","year":"2011","journal-title":"Am. J. Physiol.-Cell Physiol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1681\/ASN.V12102003","article-title":"Role of KCNE1-dependent K+ fluxes in mouse proximal tubule","volume":"12","author":"Vallon","year":"2001","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"629","DOI":"10.2337\/diab.43.5.629","article-title":"Increased renal metabolism in diabetes. Mechanism and functional implications","volume":"43","author":"Korner","year":"1994","journal-title":"Diabetes"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"F807","DOI":"10.1152\/ajprenal.1992.262.5.F807","article-title":"Glucose transporters of rat proximal tubule: Differential expression and subcellular distribution","volume":"262","author":"Dominguez","year":"1992","journal-title":"Am. J. Physiol.-Ren. Physiol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1172\/JCI116392","article-title":"Anatomical and developmental patterns of facilitative glucose transporter gene expression in the rat kidney","volume":"91","author":"Chin","year":"1993","journal-title":"J. Clin. Investig."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1113\/jphysiol.2003.046268","article-title":"Diabetes increases facilitative glucose uptake and GLUT2 expression at the rat proximal tubule brush border membrane","volume":"553","author":"Marks","year":"2003","journal-title":"J. Physiol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"F189","DOI":"10.1152\/ajprenal.00290.2023","article-title":"A comparative modeling study of the mitochondrial function of the proximal tubule and thick ascending limb cells in the rat kidney","volume":"326","author":"Layton","year":"2024","journal-title":"Am. J. Physiol.-Ren. Physiol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/969","article-title":"Renal and intestinal absorptive defects in mice lacking the NHE3 Na+\/H+ exchanger","volume":"19","author":"Schultheis","year":"1998","journal-title":"Nat. Genet."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Larsen, E.H., and Sorensen, J.N. (2024). Biophysical Analysis of a Minimalistic Kidney Model Expressing SGLT1 Reveals Crosstalk between Luminal and Lateral Membranes and a Plausible Mechanism of Isosmotic Transport. Biomolecules, 14.","DOI":"10.20944\/preprints202406.1779.v1"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"C555","DOI":"10.1152\/ajpcell.00475.2007","article-title":"Regulation of apical NHE3 trafficking by ouabain-induced activation of the basolateral Na+-K+-ATPase receptor complex","volume":"294","author":"Cai","year":"2008","journal-title":"Am. J. Physiol.-Cell Physiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0378-1119(02)00416-X","article-title":"New human sodium\/glucose cotransporter gene (KST1): Identification, characterization, and mutation analysis in ICCA (infantile convulsions and choreoathetosis) and BFIC (benign familial infantile convulsions) families","volume":"285","author":"Roll","year":"2002","journal-title":"Gene"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"11753","DOI":"10.1073\/pnas.1733027100","article-title":"A glucose sensor hiding in a family of transporters","volume":"100","author":"Hirayama","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1681\/ASN.2010030246","article-title":"SGLT2 mediates glucose reabsorption in the early proximal tubule","volume":"22","author":"Vallon","year":"2011","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/s41586-021-04212-9","article-title":"Structural basis of inhibition of the human SGLT2-MAP17 glucose transporter","volume":"601","author":"Niu","year":"2022","journal-title":"Nature"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1681\/ASN.2015111282","article-title":"MAP17 Is a Necessary Activator of Renal Na+\/Glucose Cotransporter SGLT2","volume":"28","author":"Coady","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41594-023-01134-0","article-title":"Transport and inhibition mechanism of the human SGLT2-MAP17 glucose transporter","volume":"31","author":"Hiraizumi","year":"2024","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"5245","DOI":"10.1038\/s41467-018-07700-1","article-title":"Inhibitor binding mode and allosteric regulation of Na+-glucose symporters","volume":"9","author":"Bisignano","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1159\/000543336","article-title":"Dapagliflozin Treatment Attenuates the Interaction between the Renal Sodium Chloride Co-Transporter and Ezrin in Hypertensive Diabetic db\/db Mice","volume":"149","author":"Gholam","year":"2025","journal-title":"Nephron"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/dom.12127","article-title":"Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes","volume":"15","author":"Wie","year":"2013","journal-title":"Diabetes Obes. Metab."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.clinthera.2019.01.001","article-title":"Effects of Sodium-glucose Cotransporter 2 Inhibitor Monotherapy on Weight Changes in Patients with Type 2 Diabetes Mellitus: A Bayesian Network Meta-analysis","volume":"41","author":"Wang","year":"2019","journal-title":"Clin. Ther."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s13300-013-0030-2","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple rising doses of empagliflozin in patients with type 2 diabetes mellitus","volume":"4","author":"Heise","year":"2013","journal-title":"Diabetes Ther."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in Patients with Chronic Kidney Disease","volume":"388","author":"The","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.2337\/dc13-2105","article-title":"Empagliflozin as add-on to metformin in patients with type 2 diabetes: A 24-week, randomized, double-blind, placebo-controlled trial","volume":"37","author":"Haring","year":"2014","journal-title":"Diabetes Care"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12933-016-0491-5","article-title":"Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: Comparison with sitagliptin","volume":"16","author":"Hayashi","year":"2017","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1136\/bmj.316.7134.823","article-title":"Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23)","volume":"316","author":"Turner","year":"1998","journal-title":"BMJ"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1210\/jc.2011-2260","article-title":"Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin","volume":"97","author":"Bolinder","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"E50","DOI":"10.5888\/pcd17.200076","article-title":"Early-Onset Type 2 Diabetes as a Risk Factor for End-Stage Renal Disease in Patients with Diabetic Kidney Disease","volume":"17","author":"Zheng","year":"2020","journal-title":"Prev. Chronic Dis."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1681\/ASN.2016121341","article-title":"Chronic Fluid Overload and Mortality in ESRD","volume":"28","author":"Zoccali","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1681\/ASN.V10122569","article-title":"Glomerular hyperfiltration in experimental diabetes mellitus: Potential role of tubular reabsorption","volume":"10","author":"Vallon","year":"1999","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","article-title":"Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus","volume":"129","author":"Cherney","year":"2014","journal-title":"Circulation"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"F1041","DOI":"10.1152\/ajprenal.00005.2024","article-title":"SGLT2-independent effects of canagliflozin on NHE3 and mitochondrial complex I activity inhibit proximal tubule fluid transport and albumin uptake","volume":"326","author":"Albalawy","year":"2024","journal-title":"Am. J. Physiol.-Ren. Physiol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"F414","DOI":"10.1152\/ajprenal.00174.2007","article-title":"Dipeptidyl peptidase IV inhibition downregulates Na+-H+ exchanger NHE3 in rat renal proximal tubule","volume":"294","author":"Girardi","year":"2008","journal-title":"Am. J. Physiol.-Ren. Physiol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1161\/01.RES.43.3.465","article-title":"Mechanism of adenosine-mediated decreases in glomerular filtration rate in dogs","volume":"43","author":"Osswald","year":"1978","journal-title":"Circ. Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"5872","DOI":"10.1038\/s41598-024-81973-z","article-title":"SGLT2 inhibitors reduce the risk of renal failure in CKD stage 5 patients with Type 2 DM","volume":"15","author":"Huang","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"F194","DOI":"10.1152\/ajprenal.00520.2013","article-title":"SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice","volume":"306","author":"Vallon","year":"2014","journal-title":"Am. J. Physiol.-Ren. Physiol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1002\/phar.4615","article-title":"Albuminuria-based stratification of end-stage kidney disease progression and mortality with sodium-glucose cotransporter 2 inhibitors (SGLT2i): A retrospective cohort study in type 2 diabetes and chronic kidney disease","volume":"44","author":"Chang","year":"2024","journal-title":"Pharmacotherapy"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"101334","DOI":"10.1016\/j.xcrm.2023.101334","article-title":"Dapagliflozin protects against chronic heart failure in mice by inhibiting macrophage-mediated inflammation, independent of SGLT2","volume":"4","author":"Wu","year":"2023","journal-title":"Cell Rep. Med."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Gholam, M.F., Liu, L.P., Searcy, L.A., Denslow, N.D., and Alli, A.A. (2023). Dapagliflozin Treatment Augments Bioactive Phosphatidylethanolamine Concentrations in Kidney Cortex Membrane Fractions of Hypertensive Diabetic db\/db Mice and Alters the Density of Lipid Rafts in Mouse Proximal Tubule Cells. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24021408"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1159\/000496617","article-title":"Effect of Dapagliflozin Treatment on the Expression of Renal Sodium Transporters\/Channels on High-Fat Diet Diabetic Mice","volume":"142","author":"Ma","year":"2019","journal-title":"Nephron"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1038\/ki.2012.234","article-title":"Podocyte detachment and reduced glomerular capillary endothelial fenestration promote kidney disease in type 2 diabetic nephropathy","volume":"82","author":"Weil","year":"2012","journal-title":"Kidney Int."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"111785","DOI":"10.1016\/j.intimp.2024.111785","article-title":"Dapagliflozin prevents kidney podocytes pyroptosis via miR-155-5p\/HO-1\/NLRP3 axis modulation","volume":"131","author":"Zhang","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Guo, R., Wang, P., Zheng, X., Cui, W., Shang, J., and Zhao, Z. (2022). SGLT2 inhibitors suppress epithelial-mesenchymal transition in podocytes under diabetic conditions via downregulating the IGF1R\/PI3K pathway. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.897167"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"108409","DOI":"10.1016\/j.jdiacomp.2023.108409","article-title":"Amelioration of diabetic kidney injury with dapagliflozin is associated with suppressing renal HMGB1 expression and restoring autophagy in obese mice","volume":"37","author":"Feng","year":"2023","journal-title":"J. Diabetes Its Complicat."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.biopha.2018.10.100","article-title":"Dapagliflozin attenuates early markers of diabetic nephropathy in fructose-streptozotocin-induced diabetes in rats","volume":"109","author":"Oraby","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41419-025-07396-4","article-title":"REDD1 expression in podocytes facilitates renal inflammation and pyroptosis in streptozotocin-induced diabetic nephropathy","volume":"16","author":"Sunilkumar","year":"2025","journal-title":"Cell Death Dis."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Xuan, M.Y., Piao, S.G., Ding, J., Nan, Q.Y., Piao, M.H., Jiang, Y.J., Zheng, H.L., Jin, J.Z., and Li, C. (2021). Dapagliflozin Alleviates Renal Fibrosis by Inhibiting RIP1-RIP3-MLKL-Mediated Necroinflammation in Unilateral Ureteral Obstruction. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.798381"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"294","DOI":"10.5582\/bst.2016.01077","article-title":"Serum levels of RIPK3 and troponin I as potential biomarkers for predicting impaired left ventricular function in patients with myocardial infarction with ST segment elevation and normal troponin I levels prior percutaneous coronary intervention","volume":"10","author":"Kashlov","year":"2016","journal-title":"Biosci. Trends"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"121671","DOI":"10.1016\/j.lfs.2023.121671","article-title":"Dapagliflozin delays renal fibrosis in diabetic kidney disease by inhibiting YAP\/TAZ activation","volume":"322","author":"Feng","year":"2023","journal-title":"Life Sci."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Zeng, J., Huang, H., Zhang, Y., Lv, X., Cheng, J., Zou, S.J., Han, Y., Wang, S., Gong, L., and Peng, Z. (2023). Dapagliflozin alleviates renal fibrosis in a mouse model of adenine-induced renal injury by inhibiting TGF-\u03b21\/MAPK mediated mitochondrial damage. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1095487"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Huang, F., Zhao, Y., Wang, Q., Hillebrands, J.L., van den Born, J., Ji, L., An, T., and Qin, G. (2019). Dapagliflozin Attenuates Renal Tubulointerstitial Fibrosis Associated with Type 1 Diabetes by Regulating STAT1\/TGF\u03b21 Signaling. Front. Endocrinol., 10.","DOI":"10.3389\/fendo.2019.00441"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"108687","DOI":"10.1016\/j.jdiacomp.2024.108687","article-title":"Dapagliflozin attenuates renal fibrosis by suppressing angiotensin II\/TGF\u03b2 signaling in diabetic mice","volume":"38","author":"Jiang","year":"2024","journal-title":"J. Diabetes Its Complicat."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.cmet.2020.06.020","article-title":"SGLT2 Inhibition Mediates Protection from Diabetic Kidney Disease by Promoting Ketone Body-Induced mTORC1 Inhibition","volume":"32","author":"Tomita","year":"2020","journal-title":"Cell Metab."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jacbts.2018.07.006","article-title":"Empagliflozin Increases Cardiac Energy Production in Diabetes: Novel Translational Insights into the Heart Failure Benefits of SGLT2 Inhibitors","volume":"3","author":"Verma","year":"2018","journal-title":"JACC Basic Transl. Sci."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"108930","DOI":"10.1016\/j.jdiacomp.2024.108930","article-title":"Dapagliflozin has protective effects on palmitate-induced renal tubular epithelial cells by enhancing mitochondrial function and reducing oxidative stress","volume":"39","author":"Ding","year":"2025","journal-title":"J. Diabetes Its Complicat."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s10557-017-6725-2","article-title":"SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3\/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor","volume":"31","author":"Ye","year":"2017","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"e176708","DOI":"10.1172\/JCI176708","article-title":"SGLT2 inhibition alters substrate utilization and mitochondrial redox in healthy and failing rat hearts","volume":"134","author":"Goedeke","year":"2024","journal-title":"J. Clin. Investig."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Yu, Y.W., Que, J.Q., Liu, S., Huang, K.Y., Qian, L., Weng, Y.B., Rong, F.N., Wang, L., Zhou, Y.Y., and Xue, Y.J. (2021). Sodium-Glucose Co-transporter-2 Inhibitor of Dapagliflozin Attenuates Myocardial Ischemia\/Reperfusion Injury by Limiting NLRP3 Inflammasome Activation and Modulating Autophagy. Front. Cardiovasc. Med., 8.","DOI":"10.3389\/fcvm.2021.768214"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/s13098-023-01196-6","article-title":"The influence of dapagliflozin on cardiac remodeling, myocardial function and metabolomics in type 1 diabetes mellitus rats","volume":"15","author":"Rodrigues","year":"2023","journal-title":"Diabetol. Metab. Syndr."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12933-017-0621-8","article-title":"Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: A pilot study","volume":"16","author":"Solini","year":"2017","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.jacc.2024.02.020","article-title":"Water Conservation Overrides Osmotic Diuresis During SGLT2 Inhibition in Patients with Heart Failure","volume":"83","author":"Marton","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1111\/dom.14352","article-title":"Dapagliflozin effects on lung fluid volumes in patients with heart failure and reduced ejection fraction: Results from the DEFINE-HF trial","volume":"23","author":"Nassif","year":"2021","journal-title":"Diabetes Obes. Metab."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1161\/CIRCULATIONAHA.119.044235","article-title":"Effect of Empagliflozin on Erythropoietin Levels, Iron Stores, and Red Blood Cell Morphology in Patients with Type 2 Diabetes Mellitus and Coronary Artery Disease","volume":"141","author":"Mazer","year":"2020","journal-title":"Circulation"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"103316","DOI":"10.1016\/j.resp.2019.103316","article-title":"Targeting oxidative stress, proinflammatory cytokines, apoptosis and toll like receptor 4 by empagliflozin to ameliorate bleomycin-induced lung fibrosis","volume":"273","author":"Kabel","year":"2020","journal-title":"Respir. Physiol. Neurobiol."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Jeong, H.E., Park, S., Noh, Y., Bea, S., Filion, K.B., Yu, O.H.Y., Jang, S.H., Cho, Y.M., Yon, D.K., and Shin, J.Y. (2023). Association of adverse respiratory events with sodium-glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors among patients with type 2 diabetes in South Korea: A nationwide cohort study. BMC Med., 21.","DOI":"10.1186\/s12916-023-02765-2"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"e071380","DOI":"10.1136\/bmj-2022-071380","article-title":"Novel antihyperglycaemic drugs and prevention of chronic obstructive pulmonary disease exacerbations among patients with type 2 diabetes: Population based cohort study","volume":"379","author":"Pradhan","year":"2022","journal-title":"BMJ"},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Xu, J., Kitada, M., Ogura, Y., Liu, H., and Koya, D. (2021). Dapagliflozin Restores Impaired Autophagy and Suppresses Inflammation in High Glucose-Treated HK-2 Cells. Cells, 10.","DOI":"10.3390\/cells10061457"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1111\/dom.14060","article-title":"Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 52-week results from a randomized controlled trial","volume":"22","author":"Mathieu","year":"2020","journal-title":"Diabetes Obes. Metab."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"e14150","DOI":"10.1097\/MD.0000000000014150","article-title":"Ketoacidosis with euglycemia in a patient with type 2 diabetes mellitus taking dapagliflozin: A case report","volume":"98","author":"Yeo","year":"2019","journal-title":"Medicine"},{"key":"ref_103","first-page":"e63168","article-title":"A Case of Fournier\u2019s Gangrene Following the Initiation of Dapagliflozin","volume":"16","author":"Shaykh","year":"2024","journal-title":"Cureus"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s13098-023-01130-w","article-title":"Exercise mitigates Dapagliflozin-induced skeletal muscle atrophy in STZ-induced diabetic rats","volume":"15","author":"Yang","year":"2023","journal-title":"Diabetol. Metab. Syndr."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13098-017-0255-8","article-title":"A randomized controlled trial comparing the effects of dapagliflozin and DPP-4 inhibitors on glucose variability and metabolic parameters in patients with type 2 diabetes mellitus on insulin","volume":"9","author":"Nomoto","year":"2017","journal-title":"Diabetol. Metab. Syndr."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/dom.13882","article-title":"Comparison of the effects of gemigliptin and dapagliflozin on glycaemic variability in type 2 diabetes: A randomized, open-label, active-controlled, 12-week study (STABLE II study)","volume":"22","author":"Kwak","year":"2020","journal-title":"Diabetes Obes. Metab."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/dom.12385","article-title":"Canagliflozin in Asian patients with type 2 diabetes on metformin alone or metformin in combination with sulphonylurea","volume":"17","author":"Ji","year":"2015","journal-title":"Diabetes Obes. Metab."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1111\/dom.12954","article-title":"Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year","volume":"19","author":"Lundkvist","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.2215\/CJN.08900722","article-title":"Estimated Lifetime Benefit of Combined RAAS and SGLT2 Inhibitor Therapy in Patients with Albuminuric CKD without Diabetes","volume":"17","author":"Vart","year":"2022","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1186\/s12933-024-02481-y","article-title":"Dapagliflozin mitigates cellular stress and inflammation through PI3K\/AKT pathway modulation in cardiomyocytes, aortic endothelial cells, and stem cell-derived beta cells","volume":"23","author":"Alsereidi","year":"2024","journal-title":"Cardiovasc. Diabetol."}],"container-title":["Pathophysiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1873-149X\/33\/3\/68\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T09:02:09Z","timestamp":1789030929000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1873-149X\/33\/3\/68"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":110,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["pathophysiology33030068"],"URL":"https:\/\/doi.org\/10.3390\/pathophysiology33030068","relation":{},"ISSN":["1873-149X"],"issn-type":[{"value":"1873-149X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,10]]}}}